Contribution of classical end-joining to PTEN inactivation in p53-mediated glioblastoma formation and drug-resistant survival
We know that defects in DNA repair genes are associated with cancer development. Here the authors eliminate XRCC4, a non-homologous end-joining protein, and p53 in the developing brain and find that this causes glioblastoma development as a consequence of reduced PTEN function.
Guardado en:
Autores principales: | Youn-Jung Kang, Barbara Balter, Eva Csizmadia, Brian Haas, Himanshu Sharma, Roderick Bronson, Catherine T. Yan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f33589217b7d48c4b64850b9eada2abb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Correction: Corrigendum: Contribution of classical end-joining to PTEN inactivation in p53-mediated glioblastoma formation and drug-resistant survival
por: Youn-Jung Kang, et al.
Publicado: (2017) -
Causes and Effects of Loss of Classical Nonhomologous End Joining Pathway in Parasitic Eukaryotes
por: Anna Nenarokova, et al.
Publicado: (2019) -
WRN regulates pathway choice between classical and alternative non-homologous end joining
por: Raghavendra A. Shamanna, et al.
Publicado: (2016) -
BRCA2 antagonizes classical and alternative nonhomologous end-joining to prevent gross genomic instability
por: Jinhua Han, et al.
Publicado: (2017) -
Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment
por: Mohsen Valikhani, et al.
Publicado: (2021)